Read on Twitter
#SNG Happy new year fellow holders. I wanted to give you my detailed thoughts on where I think we are all things @Synairgenplc
1. Phase III start is imminent in 26 countries - led by Parexel (world-class global CRO).
2. FDA is providing guidance/advice on the P3 design.
1. Phase III start is imminent in 26 countries - led by Parexel (world-class global CRO).
2. FDA is providing guidance/advice on the P3 design.
3. Hospitals full of Covid patients (especially in US) and a huge need as it will take months for the mass roll-out of vaccines (with many concerns surrounding uptake)
4. Home trial in progress, reported to be expanding to the US - huge need for home early-stage Covid treatment
4. Home trial in progress, reported to be expanding to the US - huge need for home early-stage Covid treatment
5. Company fully funded following placement, no pressure to sell IP to big pharma.
6. SNG001 is developed as a broad spectrum antiviral and NOT a pure Covid-play (as per COPD trials and many years of research across indications..i.e. Asthma)
6. SNG001 is developed as a broad spectrum antiviral and NOT a pure Covid-play (as per COPD trials and many years of research across indications..i.e. Asthma)
7. 100,000 doses target for January - aim also to offer to governments (pending succesful interim P3 data) as a stockpiled drug to prevent further epidemics/pandemics.
8. Phase II peer-reviewed in The Lancet.
8. Phase II peer-reviewed in The Lancet.
9. The scientific team led by recently knighted Prof. Holgate considered some of the best respiratory care experts on earth.
10. COPD - related use of SNG001 itself worth in billions for any potential partners - COPD/flu complications second biggest reason for hospitalisation.
10. COPD - related use of SNG001 itself worth in billions for any potential partners - COPD/flu complications second biggest reason for hospitalisation.
11. SNG included by the US Senate in the context of Activ-2.
12. Managed Acces Program (MAP) signed with Clinigen to facilitate distribution.
12. Managed Acces Program (MAP) signed with Clinigen to facilitate distribution.
13. Possible treatment for long covid. Science works theoretically & will be tested on p3 trial at 60 & 90 days. Market of 10% of all covid sufferers.
14. Despite vaccine roll-out and the SNG SP dropping Numis have maintained target. (Numis are also the joint broker for #NCYT)
14. Despite vaccine roll-out and the SNG SP dropping Numis have maintained target. (Numis are also the joint broker for #NCYT)
#SNG Below’s target price of £4.20 I think is conservative. If phase 3 trials are passed (which I think they will be) I see a conservative target of £10 to be achieved in 12 months with sales, EUA and global roll out.
